Analyst Reco. Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
74.19 ^USD	-0.93%		+3.73%	-6.78%

04-30	North American Morning Briefing : More Earnings -2-	DJ
04-29	Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	04-29	MT
Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90	04-29	MT
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing	04-02	MT
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating	03-28	MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating	03-26	MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating	03-26	MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating	03-26	MT
Baird Initiates Axsome Therapeutics With Outperform Rating, Price Target is $108	03-19	MT
Mizuho Cuts PT on Axsome Therapeutics to $108 From $112 After Release of AD Agitation Study Data Faces Delays, Keeps Buy Rating	02-26	MT
UBS Adjusts Axsome Therapeutics Price Target to $107 From $111, Maintains Buy Rating	02-21	MT
RBC Trims Price Target on Axsome Therapeutics to $123 From $126, Notes 'Disappointing' Delay in Data From ADVANCE-2 Trial; Outperform Kept	02-21	MT
Mizuho Raises PT on Axsome Therapeutics to $112 From $90 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	02-15	MT
UBS Initiates Axsome Therapeutics With Buy Rating, $111 Price Target	02-06	MT
RBC Initiates Axsome Therapeutics at Outperform With $126 Price Target, Cites Auvelity Launch, Stable Cash Flows From Sunosi, 'Underappreciated Pipeline Optionality'	01-25	MT
Piper Sandler Raises Price Target on Axsome Therapeutics to $113 From $90, Maintains Overweight Rating	01-16	MT
Citigroup Initiates Axsome Therapeutics With Buy Rating, Price Target is $125	12-13	MT
Mizuho Reduces Price Target on Axsome Therapeutics to $90 From $100, Reflecting Changes in the Model, Keeps Buy Rating	11-10	MT
Mizuho Increases Price Target on Axsome Therapeutics to $100 From $95, Maintains Buy Rating	11/08/23	MT
HC Wainwright Adjusts Price Target on Axsome Therapeutics to $180 From $190, Keeps Buy Rating	08/08/23	MT
BofA Securities Upgrades Axsome Therapeutics to Neutral From Underperform, Adjusts Price Target to $81 From $59	08/08/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Analyst Reco.

Filters